Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) Equity Average (2022 - 2025)

TriSalus Life Sciences' Equity Average history spans 4 years, with the latest figure at -$30.3 million for Q4 2025.

  • For Q4 2025, Equity Average fell 30.78% year-over-year to -$30.3 million; the TTM value through Dec 2025 reached -$30.3 million, down 30.78%, while the annual FY2025 figure was -$29.9 million, 12.83% down from the prior year.
  • Equity Average reached -$30.3 million in Q4 2025 per TLSIW's latest filing, down from -$23.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$9.4 million in Q4 2023 to a low of -$191.5 million in Q2 2023.
  • Average Equity Average over 4 years is -$76.8 million, with a median of -$30.6 million recorded in 2024.
  • Peak YoY movement for Equity Average: skyrocketed 94.33% in 2023, then crashed 146.78% in 2024.
  • A 4-year view of Equity Average shows it stood at -$165.5 million in 2022, then surged by 94.33% to -$9.4 million in 2023, then crashed by 146.78% to -$23.2 million in 2024, then crashed by 30.78% to -$30.3 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Equity Average are -$30.3 million (Q4 2025), -$23.1 million (Q3 2025), and -$26.9 million (Q2 2025).